Imagine designing a medicine that works perfectly in the body but disappears harmlessly once it hits the water system. This project creates a digital toolkit to help chemists build these 'green' drugs from the start. It also uses smart sensors and AI to clean up the factory process, reducing the amount of harsh chemicals used for rinsing equipment.
Pharmaceutical companies face increasing pressure to reduce the environmental toxicity of their drugs and the chemical waste generated during manufacturing.
A toolkit including in-silico drug design software, laser-based sensors for rinsing reduction, an AI-optimized Continuous Biomanufacturing line, and a registry of pharmaceutical micropollutants.
If you are a drug manufacturer dealing with high chemical waste and water pollution—this project developed a Continuous Biomanufacturing line and AI-enabled optimization that reduces rinsing chemicals and energy use.
If you are a water treatment facility dealing with undetected drug residues in wastewater—this project developed a registry of pharmaceutical micropollutants and laser-based sensors to better track environmental toxins.
If you are a drug discovery startup dealing with expensive late-stage toxicity failures—this project developed in-silico 'green-by-design' tools that predict environmental fate and toxicity before the drug is even made.
Based on available project data, specific pricing for the tools is not provided, though the project received an EU contribution of EUR 7,518,062 for development.
Yes, the project specifically aims to develop a robust Continuous Biomanufacturing line (CBM) using AI-enabled process optimization for industrial efficiency.
Based on available project data, specific licensing terms are not mentioned, but the project includes a robust exploitation plan for its deliverables.
Yes, it provides a comprehensive Life Cycle Assessment (LCA) and a registry of micropollutants to help companies meet environmental safety standards.
The project period runs from 2022-06-01 to 2025-11-30, suggesting the final tools will be ready toward the end of 2025.
The consortium is heavily industry-weighted with a 68% industry ratio, comprising 13 industrial partners including 7 SMEs. This strong commercial presence, spanning 11 countries, indicates that the project is driven by market needs rather than pure academic curiosity, focusing on practical application in pharmaceutical manufacturing.
Contact RISA SICHERHEITSANALYSEN GMBH in Germany
Contact us to connect with the ENVIROMED consortium for licensing AI-driven green manufacturing tools.
